Logo image of QTRX

QUANTERIX CORP (QTRX) Stock Fundamental Analysis

NASDAQ:QTRX - Nasdaq - US74766Q1013 - Common Stock - Currency: USD

5.16  +0.27 (+5.52%)

After market: 5.16 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to QTRX. QTRX was compared to 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for QTRX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, QTRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

QTRX had negative earnings in the past year.
In the past year QTRX has reported a negative cash flow from operations.
QTRX had negative earnings in each of the past 5 years.
QTRX had a negative operating cash flow in each of the past 5 years.
QTRX Yearly Net Income VS EBIT VS OCF VS FCFQTRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

QTRX has a Return On Assets of -12.22%. This is comparable to the rest of the industry: QTRX outperforms 50.91% of its industry peers.
QTRX has a Return On Equity (-15.06%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -12.22%
ROE -15.06%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QTRX Yearly ROA, ROE, ROICQTRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

QTRX's Gross Margin of 59.98% is amongst the best of the industry. QTRX outperforms 83.64% of its industry peers.
QTRX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for QTRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5Y5.05%
QTRX Yearly Profit, Operating, Gross MarginsQTRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

7

2. Health

2.1 Basic Checks

QTRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for QTRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QTRX Yearly Shares OutstandingQTRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
QTRX Yearly Total Debt VS Total AssetsQTRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

QTRX has an Altman-Z score of 0.68. This is a bad value and indicates that QTRX is not financially healthy and even has some risk of bankruptcy.
QTRX has a Altman-Z score of 0.68. This is in the lower half of the industry: QTRX underperforms 60.00% of its industry peers.
There is no outstanding debt for QTRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.68
ROIC/WACCN/A
WACC10.58%
QTRX Yearly LT Debt VS Equity VS FCFQTRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

QTRX has a Current Ratio of 8.66. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.66, QTRX belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
QTRX has a Quick Ratio of 7.88. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
QTRX has a better Quick ratio (7.88) than 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 8.66
Quick Ratio 7.88
QTRX Yearly Current Assets VS Current LiabilitesQTRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

5

3. Growth

3.1 Past

QTRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.77%.
The Revenue has grown by 38.50% in the past year. This is a very strong growth!
QTRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.37% yearly.
EPS 1Y (TTM)-19.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)38.5%
Revenue growth 3Y7.51%
Revenue growth 5Y19.37%
Sales Q2Q%11.45%

3.2 Future

Based on estimates for the next years, QTRX will show a small growth in Earnings Per Share. The EPS will grow by 0.97% on average per year.
QTRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.03% yearly.
EPS Next Y-26.26%
EPS Next 2Y-0.21%
EPS Next 3Y9.14%
EPS Next 5Y0.97%
Revenue Next Year3.71%
Revenue Next 2Y9.36%
Revenue Next 3Y11.5%
Revenue Next 5Y16.03%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
QTRX Yearly Revenue VS EstimatesQTRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
QTRX Yearly EPS VS EstimatesQTRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QTRX. In the last year negative earnings were reported.
Also next year QTRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTRX Price Earnings VS Forward Price EarningsQTRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTRX Per share dataQTRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.21%
EPS Next 3Y9.14%

0

5. Dividend

5.1 Amount

QTRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

QUANTERIX CORP

NASDAQ:QTRX (4/22/2025, 8:00:01 PM)

After market: 5.16 0 (0%)

5.16

+0.27 (+5.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners96.04%
Inst Owner Change-0.38%
Ins Owners6.92%
Ins Owner Change2.23%
Market Cap200.16M
Analysts81.82
Price Target13.94 (170.16%)
Short Float %9.12%
Short Ratio3.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.69%
Min EPS beat(2)-15.34%
Max EPS beat(2)11.96%
EPS beat(4)3
Avg EPS beat(4)5.95%
Min EPS beat(4)-15.34%
Max EPS beat(4)19.08%
EPS beat(8)6
Avg EPS beat(8)22.98%
EPS beat(12)7
Avg EPS beat(12)3.57%
EPS beat(16)10
Avg EPS beat(16)3.72%
Revenue beat(2)2
Avg Revenue beat(2)1.42%
Min Revenue beat(2)0.1%
Max Revenue beat(2)2.75%
Revenue beat(4)3
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-0.58%
Max Revenue beat(4)2.75%
Revenue beat(8)7
Avg Revenue beat(8)5.57%
Revenue beat(12)9
Avg Revenue beat(12)2.4%
Revenue beat(16)13
Avg Revenue beat(16)4.72%
PT rev (1m)-15.46%
PT rev (3m)-30.68%
EPS NQ rev (1m)-32.32%
EPS NQ rev (3m)-65.41%
EPS NY rev (1m)-40.39%
EPS NY rev (3m)-47.97%
Revenue NQ rev (1m)-19.58%
Revenue NQ rev (3m)-20.96%
Revenue NY rev (1m)-9.61%
Revenue NY rev (3m)-9.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.18
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS4.37
BVpS8.51
TBVpS8.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.22%
ROE -15.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.98%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5Y5.05%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.11%
Cap/Sales 1.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.66
Quick Ratio 7.88
Altman-Z 0.68
F-Score4
WACC10.58%
ROIC/WACCN/A
Cap/Depr(3y)110.86%
Cap/Depr(5y)140.92%
Cap/Sales(3y)5.57%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y-26.26%
EPS Next 2Y-0.21%
EPS Next 3Y9.14%
EPS Next 5Y0.97%
Revenue 1Y (TTM)38.5%
Revenue growth 3Y7.51%
Revenue growth 5Y19.37%
Sales Q2Q%11.45%
Revenue Next Year3.71%
Revenue Next 2Y9.36%
Revenue Next 3Y11.5%
Revenue Next 5Y16.03%
EBIT growth 1Y-40.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.58%
EBIT Next 3Y14.8%
EBIT Next 5YN/A
FCF growth 1Y-69.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.56%
OCF growth 3YN/A
OCF growth 5YN/A